Role of homocysteine in end-stage renal disease

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1286-1294

  Wu, Chia Chao ^a   Zheng, Cai Mei ^b   Lin, Yuh Feng ^b   Lo, Lan ^c   Liao, Min Tser ^d   Lu, Kuo Cheng ^c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

Diabetes; Dialysis; End stage renal disease; Folic acid; Homocysteine

Indexed keywords

ACETYLCYSTEINE; DOCOSAHEXAENOIC ACID; FISH OIL; FOLIC ACID; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; MESNA; VITAMIN B GROUP;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIALYSIS; GENOTYPE; HEALTH SURVEY; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; MEDICAL LITERATURE; MEDLINE; METABOLISM; MORBIDITY; MORTALITY; NUTRITION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ANIMALS; DIALYSIS; HOMOCYSTEINE; HUMANS; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; META-ANALYSIS AS TOPIC; RENAL DIALYSIS;

EID: 84868301351     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.05.031     Document Type: Review

References (129)

1. de Jager D.J., Grootendorst D.C., Jager K.J., van Dijk P.C., Tomas L.M., Ansell D., et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009, 302:1782-1789.
2. Byrne C., Vernon P., Cohen J.J. Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA 1994, 271:34-36.
3. Chaykovska L., Tsuprykov O., Hocher B. Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab 2011, 57:455-467.
4. Kendrick J., Chonchol M.B. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nature clinical practice. Nephrology 2008, 4:672-681.
5. Bostom A.G., Carpenter M.A., Kusek J.W., Levey A.S., Hunsicker L., Pfeffer M.A., et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011, 123:1763-1770.
6. de Koning L., Hu F.B. Homocysteine lowering in end-stage renal disease: is there any cardiovascular benefit?. Circulation 2010, 121:1379-1381.
7. Anan F., Masaki T., Umeno Y., Yonemochi H., Eshima N., Saikawa T., et al. Correlations between homocysteine levels and atherosclerosis in Japanese type 2 diabetic patients. Metabolism 2007, 56:1390-1395.
8. Anan F., Takahashi N., Shimomura T., Imagawa M., Yufu K., Nawata T., et al. Hyperhomocysteinemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism 2006, 55:656-661.
9. Durand P., Prost M., Loreau N., Lussier-Cacan S., Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001, 81:645-672.
10. Anan F., Masaki T., Umeno Y., Iwao T., Yonemochi H., Eshima N., et al. Correlations of high-sensitivity C-reactive protein and atherosclerosis in Japanese type 2 diabetic patients. Eur J Endocrinol 2007, 157:311-317.
11. Nilsson K., Gustafson L., Faldt R., Andersson A., Hultberg B. Plasma homocysteine in relation to serum cobalamin and blood folate in a psychogeriatric population. Eur J Clin Invest 1994, 24:600-606.
12. Ueland P.M., Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989, 114:473-501.
13. Durand P., Blache D. Enhanced platelet thromboxane synthesis and reduced macrophage-dependent fibrinolytic activity related to oxidative stress in oral contraceptive-treated female rats. Atherosclerosis 1996, 121:205-216.
14. Ueland P.M., Mansoor M.A., Guttormsen A.B., Muller F., Aukrust P., Refsum H., et al. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status-a possible element of the extracellular antioxidant defense system. J Nutr 1996, 126:1281S-1284S.
15. Bostom A., Brosnan J.T., Hall B., Nadeau M.R., Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995, 116:59-62.
16. Perna A.F., Ingrosso D., Zappia V., Galletti P., Capasso G., De Santo N.G. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest 1993, 91:2497-2503.
17. Stenvinkel P., Karimi M., Johansson S., Axelsson J., Suliman M., Lindholm B., et al. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease?. J Intern Med 2007, 261:488-499.
18. van Guldener C., Stehouwer C.D. Homocysteine and methionine metabolism in renal failure. Semin Vasc Med 2005, 5:201-208.
19. Hultberg B., Andersson A., Isaksson A. Metabolism of homocysteine, its relation to the other cellular thiols and its mechanism of cell damage in a cell culture line (human histiocytic cell line U-937). Biochim Biophys Acta 1995, 1269:6-12.
20. Tamura T., Johnston K.E., Bergman S.M. Homocysteine and folate concentrations in blood from patients treated with hemodialysis. J Am Soc Nephrol 1996, 7:2414-2418.
21. Wierzbicki A.S. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 2007, 4:143-150.
22. Pastore A., De Angelis S., Casciani S., Ruggia R., Di Giovamberardino G., Noce A., et al. Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes. Clin Chem 2006, 52:145-148.
23. Iemitsu M., Murakami H., Sanada K., Yamamoto K., Kawano H., Gando Y., et al. Lack of carotid stiffening associated with MTHFR 677TT genotype in cardiorespiratory fit adults. Physiol Genomics 2010, 42:259-265.
24. Tai H.C., Yang W.C., Chen T.W., Lin C.C. Are homocysteine and MTHFR genotype polymorphism associated with arteriovenous fistula patency?. Am J Kidney Dis 2005, 46:993-994. [author reply 994].
25. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291:565-575.
26. Lewis S.J., Ebrahim S., Davey Smith G. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?. BMJ 2005, 331:1053.
27. Aucella F., Margaglione M., Grandone E., Vigilante M., Gatta G., Forcella M., et al. The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study. Nephrol Dial Transplant 2005, 20:382-386.
28. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969, 56:111-128.
29. Clarke R., Lewington S., Landray M. Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int Suppl 2003, S131-S133.
30. Austen S.K., Coombes J.S., Fassett R.G. Homocysteine and cardiovascular disease in renal disease. Nephrology (Carlton) 2003, 8:285-295.
31. Van Campenhout A., Moran C.S., Parr A., Clancy P., Rush C., Jakubowski H., et al. Role of homocysteine in aortic calcification and osteogenic cell differentiation. Atherosclerosis 2009, 202:557-566.
32. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042-1050.
33. Thambyrajah J., Townend J.N. Homocysteine and atherothrombosis-mechanisms for injury. Eur Heart J 2000, 21:967-974.
34. Ciaccio M., Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol 2010, 5:30-36.
35. Chaykovska L., Tsuprykov O., Hocher B. Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy. Clin Lab 2011, 57:455-467.
36. Zoccali C., Benedetto F.A., Mallamaci F., Tripepi G., Fermo I., Foca A., et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 2000, 18:1207-1213.
37. Kalantar-Zadeh K., Block G., Humphreys M.H., McAllister C.J., Kopple J.D. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004, 15:442-453.
38. Marcus J., Sarnak M.J., Menon V. Homocysteine lowering and cardiovascular disease risk: lost in translation. Can J Cardiol 2007, 23:707-710.
39. Pecoits-Filho R., Lindholm B., Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 2002, 17(Suppl. 11):28-31.
40. Gorelick P.B. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci 2010, 1207:155-162.
41. el-Mesallamy H., Suwailem S., Hamdy N. Evaluation of C-reactive protein, endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients. Mediators Inflamm 2007, 2007:73635.
42. Streja D., Cressey P., Rabkin S.W. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 2003, 17:120-127.
43. Herrmann W., Obeid R. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients. Clin Chem Lab Med 2005, 43:1039-1047.
44. Wijekoon E.P., Brosnan M.E., Brosnan J.T. Homocysteine metabolism in diabetes. Biochem Soc Trans 2007, 35:1175-1179.
45. Lu K.C., Ma W.Y., Chen C.C., Hung K.C., Chen H.S., Wu C.C., et al. Influence of diabetes on homocysteine-lowering therapy in chronic hemodialysis patients. Clin Chim Acta 2011, 412:1234-1239.
46. Herrmann W., Schorr H., Obeid R., Makowski J., Fowler B., Kuhlmann M.K. Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clin Chem 2005, 51:891-897.
47. Gillum R. Distribution of serum total homocysteine and its association with diabetes and cardiovascular risk factors of the insulin resistance syndrome in Mexican American men: the Third National Health and Nutrition Examination Survey. Nutr J 2003, 2:6.
48. Jacobs R.L., House J.D., Brosnan M.E., Brosnan J.T. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 1998, 47:1967-1970.
49. Proceedings of the 7th International Conference on Homocysteine Metabolism. June, 21-25, 2009. Prague, Czech Republic; and the Annual International Meeting on Inborn Errors of Metabolism. Fulda, Germany. J Inherit Metab Dis 2011, 34:1-157.
50. Cole N.W., Weaver K.R., Walcher B.N., Adams Z.F., Miller R.R. Hyperglycemia-induced membrane lipid peroxidation and elevated homocysteine levels are poorly attenuated by exogenous folate in embryonic chick brains. Comp Biochem Physiol B Biochem Mol Biol 2008, 150:338-343.
51. Rosolova H., Simon J., Mayer O., Racek J., Dierze T., Jacobsen D.W. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. Physiol Res 2002, 51:93-98.
52. Masuda Y., Kubo A., Kokaze A., Yoshida M., Fukuhara N., Takashima Y. Factors associated with serum total homocysteine level in type 2 diabetes. Environ Health Prev Med 2008, 13:148-155.
53. Gallieni M., Musetti C., Granata A., Olivi L., Bertoli S. Metabolic consequences of peritoneal dialysis treatment. Panminerva Med 2009, 51:175-185.
54. Wilcken D.E., Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976, 57:1079-1082.
55. Gonin J.M. Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens 2005, 14:277-281.
56. Heinz J., Kropf S., Luley C., Dierkes J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis 2009, 54:478-489.
57. Dierkes J., Domrose U., Bosselmann K.P., Neumann K.H., Luley C. Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease. J Ren Nutr 2001, 11:67-72.
58. Sunder-Plassmann G., Fodinger M., Buchmayer H., Papagiannopoulos M., Wojcik J., Kletzmayr J., et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000, 11:1106-1116.
59. Sombolos K., Papaioannou A., Christidou F., Natse T., Bamichas G., Gionanlis L., et al. The effect of two different doses comprising the simultaneous administration of intravenous B-complex vitamins and oral folic acid on serum homocysteine levels in hemodialysis patients. Int Urol Nephrol 2006, 38:725-730.
60. Disorders of homocysteine metabolism: from rare genetic defects to common risk factors. Eur J Pediatr 1998, 157(Suppl. 2):S39-S142.
61. Bostom A.G., Shemin D., Lapane K.L., Hume A.L., Yoburn D., Nadeau M.R., et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996, 49:147-152.
62. Azadibakhsh N., Hosseini R.S., Atabak S., Nateghiyan N., Golestan B., Rad A.H. Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients. Saudi J Kidney Dis Transpl 2009, 20:779-788.
63. Nanayakkara P.W., van Guldener C., ter Wee P.M., Scheffer P.G., van Ittersum F.J., Twisk J.W., et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 2007, 167:1262-1270.
64. Qin X., Huo Y., Langman C.B., Hou F., Chen Y., Matossian D., et al. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2011, 6:482-488.
65. Jamison R.L., Hartigan P., Kaufman J.S., Goldfarb D.S., Warren S.R., Guarino P.D., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298:1163-1170.
66. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354:1567-1577.
67. Mann J.F., Sheridan P., McQueen M.J., Held C., Arnold J.M., Fodor G., et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study. Nephrol Dial Transplant 2008, 23:645-653.
68. House A.A., Eliasziw M., Cattran D.C., Churchill D.N., Oliver M.J., Fine A., et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010, 303:1603-1609.
69. Pan Y., Guo L.L., Cai L.L., Zhu X.J., Shu J.L., Liu X.L., et al. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr 2012, 1-8.
70. Holmes M.V., Newcombe P., Hubacek J.A., Sofat R., Ricketts S.L., Cooper J., et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011, 378:584-594.
71. Tighe P., Ward M., McNulty H., Finnegan O., Dunne A., Strain J., et al. A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy. Am J Clin Nutr 2011, 93:11-18.
72. Araki A., Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987, 422:43-52.
73. Han Z.J., Cui Y., Song G., Xia H.F., Ma X. Protective effects of N-acetylcysteine on homocysteine induced injury in chick embryos. Front Biosci (Elite Ed) 2010, 2:940-947.
74. Scholze A., Rinder C., Beige J., Riezler R., Zidek W., Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004, 109:369-374.
75. Nolin T.D., Ouseph R., Himmelfarb J., McMenamin M.E., Ward R.A. Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol 2010, 5:1588-1594.
76. Nascimento M.M., Suliman M.E., Silva M., Chinaglia T., Marchioro J., Hayashi S.Y., et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int 2010, 30:336-342.
77. Urquhart B.L., Freeman D.J., Spence J.D., House A.A. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis 2007, 49:109-117.
78. McLennan P., Howe P., Abeywardena M., Muggli R., Raederstorff D., Mano M., et al. The cardiovascular protective role of docosahexaenoic acid. Eur J Pharmacol 1996, 300:83-89.
79. de Bree A., Mennen L.I., Hercberg S., Galan P. Evidence for a protective (synergistic?) effect of B-vitamins and omega-3 fatty acids on cardiovascular diseases. Eur J Clin Nutr 2004, 58:732-744.
80. Filaire E., Massart A., Portier H., Rouveix M., Rosado F., Bage A.S., et al. Effect of 6 Weeks of n-3 fatty-acid supplementation on oxidative stress in Judo athletes. Int J Sport Nutr Exerc Metab 2010, 20:496-506.
81. Chen J., Shearer G.C., Chen Q., Healy C.L., Beyer A.J., Nareddy V.B., et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 2011, 123:584-593.
82. Choi S.W., Mason J.B. Folate and carcinogenesis: an integrated scheme. J Nutr 2000, 130:129-132.
83. McMichael A.J. Food, nutrition, physical activity and cancer prevention. Authoritative report from World Cancer Research Fund provides global update. Public Health Nutr 2008, 11:762-763.
84. Shrubsole M.J., Shu X.O., Li H.L., Cai H., Yang G., Gao Y.T., et al. Dietary B vitamin and methionine intakes and breast cancer risk among Chinese women. Am J Epidemiol 2011, 173:1171-1182.
85. Wolpin B.M., Wei E.K., Ng K., Meyerhardt J.A., Chan J.A., Selhub J., et al. Prediagnostic plasma folate and the risk of death in patients with colorectal cancer. J Clin Oncol 2008, 26:3222-3228.
86. Song J., Sohn K.J., Medline A., Ash C., Gallinger S., Kim Y.I. Chemopreventive effects of dietary folate on intestinal polyps in Apc+/-Msh2-/-mice. Cancer Res 2000, 60:3191-3199.
87. Figueiredo J.C., Grau M.V., Haile R.W., Sandler R.S., Summers R.W., Bresalier R.S., et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009, 101:432-435.
88. Ebbing M., Bonaa K.H., Nygard O., Arnesen E., Ueland P.M., Nordrehaug J.E., et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009, 302:2119-2126.
89. Heinz J., Domrose U., Westphal S., Luley C., Neumann K.H., Dierkes J. Washout of water-soluble vitamins and of homocysteine during haemodialysis: effect of high-flux and low-flux dialyser membranes. Nephrology (Carlton) 2008, 13:384-389.
90. Vychytil A., Fodinger M., Papagiannopoulos M., Wolfl G., Horl W.H., Sunder-Plassmann G. Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int 1999, 55:2054-2061.
91. Brulez H.F., van Guldener C., Donker A.J., ter Wee P.M. The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 1999, 14:154-159.
92. Czupryniak A., Nowicki M., Chwatko G., Jander A., Bald E. Peritoneal clearance of homocysteine with icodextrin or standard glucose solution exchange. Nephrology (Carlton) 2005, 10:571-575.
93. Bachmann J., Tepel M., Raidt H., Riezler R., Graefe U., Langer K., et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995, 6:121-125.
94. Bostom A.G., Shemin D., Lapane K.L., Miller J.W., Sutherland P., Nadeau M., et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995, 114:93-103.
95. Robinson K., Gupta A., Dennis V., Arheart K., Chaudhary D., Green R., et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996, 94:2743-2748.
96. Vychytil A., Fodinger M., Wolfl G., Enzenberger B., Auinger M., Prischl F., et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 1998, 53:1775-1782.
97. Kunz K., Petitjean P., Lisri M., Chantrel F., Koehl C., Wiesel M.L., et al. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link?. Nephrol Dial Transplant 1999, 14:1934-1942.
98. Manns B.J., Burgess E.D., Hyndman M.E., Parsons H.G., Schaefer J.P., Scott-Douglas N.W. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999, 34:669-677.
99. Suliman M.E., Qureshi A.R., Barany P., Stenvinkel P., Filho J.C., Anderstam B., et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000, 57:1727-1735.
100. Haraki T., Takegoshi T., Kitoh C., Kajinami K., Wakasugi T., Hirai J., et al. Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease. Clin Nephrol 2001, 56:132-139.
101. Nair A.P., Nemirovsky D., Kim M., Geer E.B., Farkouh M.E., Winston J., et al. Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med 2005, 72:365-373.
102. Wrone E.M., Zehnder J.L., Hornberger J.M., McCann L.M., Coplon N.S., Fortmann S.P. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001, 60:1106-1113.
103. Anan F., Takahashi N., Shimomura T., Imagawa M., Yufu K., Nawata T., et al. Hyperhomocysteinemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism 2006, 55:656-661.
104. Bostom A.G., Shemin D., Verhoef P., Nadeau M.R., Jacques P.F., Selhub J., et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997, 17:2554-2558.
105. Moustapha A., Naso A., Nahlawi M., Gupta A., Arheart K.L., Jacobsen D.W., et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998, 97:138-141.
106. Sirrs S., Duncan L., Djurdjev O., Nussbaumer G., Ganz G., Frohlich J., et al. Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Nephrol Dial Transplant 1999, 14:738-743.
107. Dierkes J., Domrose U., Westphal S., Ambrosch A., Bosselmann H.P., Neumann K.H., et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000, 102:1964-1969.
108. Ducloux D., Bresson-Vautrin C., Kribs M., Abdelfatah A., Chalopin J.M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002, 62:1417-1422.
109. Mallamaci F., Zoccali C., Tripepi G., Fermo I., Benedetto F.A., Cataliotti A., et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002, 61:609-614.
110. Buccianti G., Baragetti I., Bamonti F., Furiani S., Dorighet V., Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004, 17:405-410.
111. Ducloux D., Klein A., Kazory A., Devillard N., Chalopin J.M. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006, 69:331-335.
112. Fodinger M., Mannhalter C., Wolfl G., Pabinger I., Muller E., Schmid R., et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997, 52:517-523.
113. Fodinger M., Wolfl G., Fischer G., Rasoul-Rockenschaub S., Schmid R., Horl W.H., et al. Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. Kidney Int 1999, 55:1072-1080.
114. Fodinger M., Buchmayer H., Heinz G., Papagiannopoulos M., Kletzmayr J., Perschl A., et al. Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patients. Am J Kidney Dis 2001, 38:77-84.
115. Nakamura T., Saionji K., Hiejima Y., Hirayama H., Tago K., Takano H., et al. Methylenetetrahydrofolate reductase genotype, vitamin B12, and folate influence plasma homocysteine in hemodialysis patients. Am J Kidney Dis 2002, 39:1032-1039.
116. Fodinger M., Buchmayer H., Heinz G., Papagiannopoulos M., Kletzmayr J., Rasoul-Rockenschaub S., et al. Effect of MTHFR 1298A->C and MTHFR 677C->T genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kdiney graft recipients. J Am Soc Nephrol 2000, 11:1918-1925.
117. Winkelmayer W.C., Huber A., Wagner O.F., Horl W.H., Sunder-Plassmann G., Fodinger M. Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B in kidney transplant recipients. Kidney Int 2005, 67:1980-1985.
118. Feix A., Fritsche-Polanz R., Kletzmayr J., Vychytil A., Horl W.H., Sunder-Plassmann G., et al. Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. Am J Kidney Dis 2001, 38:956-964.
119. Feix A., Winkelmayer W.C., Eberle C., Sunder-Plassmann G., Fodinger M. Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients. Atherosclerosis 2004, 174:43-48.
120. Fodinger M., Dierkes J., Skoupy S., Rohrer C., Hagen W., Puttinger H., et al. Effect of glutamate carboxypeptidase II and reduced folate carrier polymorphisms on folate and total homocysteine concentrations in dialysis patients. J Am Soc Nephrol 2003, 14:1314-1319.
121. Winkelmayer W.C., Eberle C., Sunder-Plassmann G., Fodinger M. Effects of the glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A) allelic variants on folate and total homocysteine levels in kidney transplant patients. Kidney Int 2003, 63:2280-2285.
122. Fodinger M., Veitl M., Skoupy S., Wojcik J., Rohrer C., Hagen W., et al. Effect of TCN2 776C>G on vitamin B12 cellular availability in end-stage renal disease patients. Kidney Int 2003, 64:1095-1100.
123. Winkelmayer W.C., Skoupy S., Eberle C., Fodinger M., Sunder-Plassmann G. Effects of TCN2 776C>G on vitamin B, folate, and total homocysteine levels in kidney transplant patients. Kidney Int 2004, 65:1877-1881.
124. Righetti M., Ferrario G.M., Milani S., Serbelloni P., La Rosa L., Uccellini M., et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003, 9:PI19-PI24.
125. Wrone E.M., Hornberger J.M., Zehnder J.L., McCann L.M., Coplon N.S., Fortmann S.P. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004, 15:420-426.
126. Righetti M., Serbelloni P., Milani S., Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006, 24:379-386.
127. Zoungas S., McGrath B.P., Branley P., Kerr P.G., Muske C., Wolfe R., et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006, 47:1108-1116.
128. Vianna A.C., Mocelin A.J., Matsuo T., Morais-Filho D., Largura A., Delfino V.A., et al. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 2007, 11:210-216.
129. Heinz J., Kropf S., Domrose U., Westphal S., Borucki K., Luley C., et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010, 121:1432-1438.